EPO and chronic kidney disease: A new class of drugs, hypoxia‐inducible factor prolyl hydroxylase inhibitors (HIF‐PHDi) was developed to increase endogenous EPO while the kidney retains some functional capacity during CKD (Maxwell & Eckardt, 2016).